The effect of Nigella sativa supplementation on glycemic status in adults: An updated systematic review and meta-analysis of randomized controlled trials

Abstract

This systematic review and meta-analysis of randomized controlled trials (RCTs) sought to evaluate the effects of Nigella sativa (N. sativa) consumption on glycemic index in adults. A systematic literature search up to December 2023 was completed in PubMed, Scopus, and Web of Science, to identify eligible RCTs. Random effects models were assessed based on the heterogeneity tests, and pooled data were determined as weighted mean differences with a 95 confidence interval. Finally, a total of 30 studies were found to be eligible for this meta-analysis. The pooled results using random effects model indicated that N. sativa supplementation significantly reduced FBS (SMD: -1.71; 95 CI: -2.11, -1.31, p <0.001; I-2= 92.7 , p-heterogeneity <0.001) and HA1c levels (SMD: -2.16; 95 CI: -3.04, -1.29, p <0.001; I-2= 95.7 , p-heterogeneity <0.001) but not effect on insulin (SMD = 0.48; 95 CI: -0.53, 1.48, P = 0.353; I-2= 96.1 , p-heterogeneity <0.001), and HOMA-IR (SMD: -0.56; 95 CI: -1.47, 0.35, p=0.229; I-2= 95.0 , p-heterogeneity <0.001).Overall, the evidence supports the consumption of N. sativa to reduce FBS and HA1c levels. Additional research, featuring extended durations and robust study designs, is necessary to determine the ideal dosage and duration of N. sativa supplementation for achieving a positive impact on glycemic markers.